
News|Articles|June 25, 2026
A Death Doula on Pancreatic Cancer and the Limits of a TV Portrayal
Author(s)Cancer Network Staff
Fact checked by: Tim Cortese, Russ Conroy
INELDA-certified death doula Kim Stravers shares a detailed account of supporting a patient with pancreatic cancer and Lynch syndrome.
Advertisement
Advertisement
Kim Stravers is a certified end-of-life doula and educator with the International End of Life Doula Association (INELDA), with additional proficiency through the National End-of-Life Doula Alliance (NEDA). She is based in the Phoenix, Arizona area, volunteers with a local hospice organization, and provides private doula services to patients navigating serious illness and their circles of care.
Related to this article

Martin Gleave, CM, MD, FRCSC, FACS, discussed perioperative therapy selection, the GUNS trial, and postoperative radiotherapy in prostate cancer.

National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.

Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.

The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.

Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.

Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.

Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn recommendations into care.
Advertisement
Advertisement

